Law360, New York (April 5, 2011, 3:46 PM EDT) -- Palmetto Pharmaceuticals LLC launched a suit Tuesday in South Carolina alleging AstraZeneca Pharmaceuticals LP’s blockbuster cholesterol-lowering drug Crestor infringes Palmetto’s patent.
The Charleston, S.C.-based drugmaker filed its complaint in the U.S. District Court for the District of South Carolina, taking issue with AstraZeneca’s manufacture and sale of Crestor. Palmetto’s patent, U.S. Patent Number 6,465,516, covers a method of stimulating nitric oxide synthase and was issued in October 2002. A re-examination certificate was issued this month.
AstraZeneca’s Crestor is an Hmg-CoA reductase inhibitor, used to treat individuals...
Palmetto Targets AstraZeneca’s Crestor In IP Suit
To view the full article, register now.
Try Law360 FREE for seven days
Already a subscriber? Click here to login
